New Modalities in the Treatment of Refractory Alopecia Areata

    May 2017 in “ InTech eBooks
    Arzu Kılıç
    From the encyclopedia
    Minoxidil →

    An essential vasodilator with some anti-androgenic effects

    Tofacitinib →

    a JAK inhibitor for alopecia areata and other autoimmune conditions

    Studysummary This review summarizes current treatments for recalcitrant alopecia areata and recent therapeutic developments targeting specific immunological pathways, reporting no new clinical results.
    Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
    The document reviewed various new treatment modalities for refractory alopecia areata (AA), emphasizing the complexity and multifactorial nature of the disease. It highlighted the limited efficacy of conventional therapies like corticosteroids and minoxidil, especially in severe cases. Novel treatments, including JAK inhibitors (tofacitinib, ruxolitinib), showed promise in reversing hair loss by targeting specific immunological pathways. Phototherapy and laser therapy had mixed results, with some studies reporting high regrowth rates. Biologic agents like dupilumab and tralokinumab, targeting cytokines and immune pathways, were under investigation. The document stressed the need for more randomized controlled studies and personalized treatment plans due to heterogeneous patient responses, underscoring the importance of continued research to develop effective treatments for AA.
    Discuss this study in the Community →

    Research cited in this study

    57 / 57 results